Abiopharma

🔍 Pegus Cheryl (Director)

Company: BOSTON SCIENTIFIC CORP (BSX)

Report Date: 2026-05-07

Detailed Transactions and Holdings:

• Acquired 3,800 shares of Deferred Stock Units (Derivative)
  Date: 2026-05-07 | Code: A | equity_swap_involved: 0 | shares_owned_after: 9,717.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3, F3
• Acquired 1,281 shares of Deferred Stock Units (Derivative)
  Date: 2026-05-07 | Code: A | equity_swap_involved: 0 | shares_owned_after: 10,998.00 | transaction_form_type: 4 | Footnotes: F1, F4, F4, F4

Footnotes:

• F1: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
• F2: Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.
• F3: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan.
• F4: Deferred stock units were granted in lieu of 50% yearly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $72,500 (representing 50% of the amount of the non-employee director compensation program's cash retainer having a value of $125,000 and committee chair retainer having a value of $20,000) divided by the closing price of the common stock on the date of grant.